Avedro gains CE mark for riboflavin formulations

  • June 12, 2012

Avedro has received CE mark approval for its newest riboflavin formulations, according to a press release.

The new formulations are designed for use in conjunction with Avedro’s KXL system.

The ParaCel formulation for transepithelial cross-linking is based on research and an associated patent by Roberto Pinelli, MD, director of the Istituto Laser Microchirurgia Oculare, the release said.

“ParaCel provides for an easier, faster and more comfortable cross-linking procedure when treating my keratoconic and ectasia patients,” Pinelli said in the release. “When using ParaCel in combination with Avedro’s KXL system, I am able to treat my keratoconic patients in a much shorter time, without the postoperative discomfort associated with removal of the epithelium.”

Avedro is currently sponsoring phase 3 corneal collagen cross-linking trials in the U.S. 

Comments

Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.

[X]